Clinical trials: Malignant Melanoma
Advanced Melanoma, Metastatic Melanoma
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with…
- Trial name
- NCT05629546
- Testing
- Cytokine-induced memory-like natural killer cells, Relatilmab, Nivolumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
Melanoma, Metastatic Melanoma
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF…
- Trial name
- NCT01495988
- Testing
- Vemurafenib, Bevacizumab, Cobimetinib
- Where
- 14 sites in United States
- Volunteers
- 10 people
- Sponsor
- Melanoma Research Foundation Breakthrough Consortium
Advanced Uveal Melanoma, Metastatic Uveal Melanoma
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
This phase I/II trial tests the safety, side effects, and best dose of PLX2853 in combination with trametinib in treating patients with uveal (eye) melanoma that has spread to other places in the body (metastatic) or nearby…
- Conditions
- Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma
- Trial name
- NCT05677373
- Testing
- BRD4 Inhibitor PLX2853, Trametinib, Computed Tomography
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Skin Cancer
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
In this study, we want to find out how likely it is for temozolomide to shrink melanoma tumors that have spread only to areas that could be removed by surgery.
- Conditions
- Melanoma, Skin Cancer, Cancer
- Trial name
- NCT00588341
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Abraxane and Temodar Plus Genasense in Advanced Melanoma
This study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in chemotherapy-naïve subjects with advanced melanoma and normal…
- Trial name
- NCT00409383
- Testing
- Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Genta Incorporated
Melanoma (Skin)
Zr89 + PET Companion Trial
Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine.
- Trial name
- NCT05279027
- Testing
- Zirconium Zr 89 Crefmirlimab Berdoxa
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.
- Trial name
- NCT03580382
- Testing
- Trametinib daily Until PD, CDX-3379 (ERBB3 antibody)
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Malignant Melanoma
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In Part 1 patients with melanoma will receive AdCD40L as mono therapy.
- Trial name
- NCT01455259
- Testing
- AdCD40L
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Melanoma (Skin)
Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim
RATIONALE: Studying samples of blood from patients treated with sargramostim in the laboratory may help doctors learn more about the effects of sargramostim on cells.
- Trial name
- NCT01388569
- Testing
- flow cytometry, immunologic technique, laboratory biomarker analysis
- Volunteers
- 48 people
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Cancer, Melanoma
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
Two part prospective study to: 1. investigate the feasibility of performing ultra-deep sequencing of plasma derived circulating tumor DNA (ctDNA) in individual patients with advanced solid tumors who are currently being treated…
- Trial name
- SPECIAL (NCT02724488)
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Melanoma, Breast Cancer
Safety Study of Modified Vaccinia Virus to Cancer
The purpose of this study is to determine the safety and maximum tolerated dose from injecting this vaccinia virus into tumors or infusion.
- Conditions
- Melanoma, Breast Cancer, Head and Neck Squamous Cell Cancer, Liver Cancer
- Trial name
- NCT00574977
- Testing
- Vaccinia virus (vvDD-CDSR)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- David Bartlett
Melanoma (Skin)
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as temozolomide, paclitaxel albumin-stabilized nanoparticle formulation, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00626405
- Testing
- bevacizumab, carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 259 sites in United States
- Volunteers
- 95 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Malignant Melanoma, Melanoma (Skin)
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda).
- Conditions
- Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Trial name
- NCT04079166
- Testing
- SCIB1 or iSCIB1+ DNA vaccine
- Where
- 15 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- Scancell Ltd
Melanoma Stage Iv
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain…
- Trial name
- ABC-X (NCT03340129)
- Testing
- Ipilimumab, Nivolumab, Stereotactic Radiotherapy
- Where
- 9 sites in Australia, Norway
- Volunteers
- 218 people
- Sponsor
- Melanoma Institute Australia
Mucosal Melanoma, PD-L1 Positive
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
Melanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average.
- Trial name
- NCT07400302
- Testing
- Sintilimab, Dacarbazine or Temozolomide, Cisplatin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- The First Hospital of Jilin University
Melanoma, Unresectable Solid Tumors
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Nivolumab (and other agents affecting the anti-programmed death-1 [anti-PD-1] pathway) have demonstrated anti-tumor activity in multiple tumor types.
- Conditions
- Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type
- Trial name
- NCT04572451
- Testing
- nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Yana Najjar
Melanoma
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.
- Trial name
- NCT02545075
- Testing
- Ipilimumab, Dacarbazine
- Where
- 8 sites in China
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer, Breast Cancer
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
- Trial name
- SBRT (NCT01777802)
- Testing
- SBRT, IMRT, Brachytherapy
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.